Advancing Precision Oncology Novartis Launches India’s First Approved Radioligand Therapy for Prostate Cancer

Novartis: In a landmark development for oncology in India, Novartis has announced the launch of Pluvicto® (lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority-approved radioligand therapy for eligible patients with Prostate-Specific Membrane Antigen (PSMA)-positive prostate cancer. This milestone signifies a major shift toward precision medicine, offering hope for patients facing advanced metastatic prostate cancer.

Addressing a Growing Health Challenge:
Prostate cancer has emerged as a significant health burden among men in India, currently ranking among the top three cancers affecting the urban male population. With approximately 250,000 cases annually, the challenge is compounded by the fact that nearly 50% of these patients are diagnosed only at the metastatic stage. At this level, treatment becomes increasingly complex, often resulting in diminished quality of life and limited therapeutic options.

The Science of Radioligand Therapy:
Pluvicto represents a sophisticated approach to cancer care. By combining a targeting compound (ligand) with a therapeutic radioisotope, the therapy is designed to bind specifically to PSMA-positive prostate cancer cells. This precision allows the radiation to damage the cancer cells while minimizing exposure to surrounding healthy tissues. This targeted delivery has the potential to:

• Delay disease progression.
• Support overall survival in defined settings.
• Significantly improve the quality of life for patients.

Expanding Access Through Infrastructure:
The introduction of Pluvicto is strategically aligned with the rapid expansion of India’s nuclear medicine ecosystem, which now boasts over 250 nuclear medicine centers nationwide.

Amitabh Dube, Country President and Managing Director, Novartis India, emphasized that the company’s focus extends beyond the medication itself. Novartis is actively partnering with hospitals, oncologists, and nuclear medicine specialists to:

• Strengthen treatment access pathways.
• Foster multidisciplinary collaboration.
• Enhance infrastructure readiness for the future of nuclear medicine.

A Commitment to Quality and Innovation:
This launch underscores Novartis’ dedication to bringing globally recognized, regulatory-approved therapies to the Indian market. Every dose is produced in Good Manufacturing Practice (GMP)-compliant facilities, ensuring the highest standards of safety and quality for patients. As Novartis collaborates with local healthcare stakeholders, the goal remains clear: to ensure that this next-generation treatment is accessible to those who need it most, ultimately transforming the landscape of advanced prostate cancer care in India.